Saxenda label drops suicidal behavior and ideation warning
The warning is gone from the liraglutide labels, but regulators have not confirmed a link between GLP-1 drugs and suicidality and researchers say monitoring should continue.
The prescribing information for Saxenda, Novo Nordisk's liraglutide injection for weight management, no longer includes a warning subsection on suicidal behavior and ideation, according to a February 2026 label revision [1]. Labeling for generic liraglutide injection was updated the same month [2].
What changed in the labels
Both the brand label and the generic version carry a "Recent Major Changes" table that lists "Suicidal Behavior and Ideation (5.9) ... (Removed) 02/2026" [1][2]. Section 5.9 now covers a different topic, Pulmonary Aspiration During General Anesthesia or Deep Sedation [1][2]. Both documents are dated "Revised: 02/2026" [1][2].
The same tables list other recent edits: the Indications and Usage section was updated in 05/2025, Patient Selection was removed from Dosage and Administration in 05/2025, Pregnancy was removed from Contraindications in 05/2025, and a Severe Gastrointestinal Adverse Reactions warning was added in 10/2025 [1][2]. The boxed warning for risk of thyroid C-cell tumors remains in both labels [1][2].
Saxenda is a GLP-1 receptor agonist given once daily by subcutaneous injection, with a recommended dose of 3 mg for weight management [1]. It is indicated, along with a reduced-calorie diet and increased physical activity, for adults and children aged 12 and older with body weight above 60 kg and obesity, and for adults with overweight plus at least one weight-related condition [1][2].
The labels do not state why the suicidal behavior and ideation subsection was removed. No reason has been disclosed in the labeling documents [1][2].
What the safety data show
A pharmacovigilance analysis published in 2026 looked at reports of suicide- and self-injury-related events for liraglutide, semaglutide and tirzepatide in EudraVigilance, the European Union's adverse-event database, covering January 1, 2021 through December 31, 2025 [3]. Among 42,941 eligible reports, suicide and self-injury events were a small share: 37 cases for liraglutide, 141 for semaglutide and 47 for tirzepatide [3].
Compared with tirzepatide, the reporting frequency of these events was higher for liraglutide (reporting odds ratio 2.54, 95% CI 1.60-4.01) and for semaglutide (reporting odds ratio 2.69, 95% CI 1.91-3.83) [3]. The authors state the findings do not establish a causal link and are only a comparison of reporting patterns; they also note that spontaneous reporting systems have limitations [3].
The analysis states that European and United States regulatory agencies have not confirmed a causal relationship between these drugs and suicidality, and that continued post-marketing monitoring is warranted as use for weight management grows [3].
Why it matters for patients
People taking Saxenda or generic liraglutide who read the prescribing information or medication guide will find the suicidal behavior and ideation warning is no longer there [1][2]. A label change is a regulatory and labeling decision; it is not the same as a finding that a risk does not exist. Neither label gives a reason for the removal [1][2], and whether GLP-1 drugs can cause or worsen suicidal thoughts remains unresolved: regulators have not confirmed a causal relationship [3], and the 2026 researchers call for continued monitoring [3].
Reporting patterns differed across the three drugs studied, but rates drawn from a spontaneous-report database do not measure how often events actually occur, and the authors caution against reading cause and effect into them [3]. Patients who want to report a suspected side effect can use the contact information printed in the labels, which direct reports to the manufacturer or to FDA MedWatch [1][2].
What happens next
No further regulatory action on this question has been announced. The labels do not say whether the same suicidal behavior and ideation language has been removed from semaglutide or tirzepatide product labeling [1][2]. The 2026 pharmacovigilance analysis provides no timeline for additional review, and neither US nor European regulators have issued a conclusion on causality [3].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.